ClinicalTrials.gg
RecruitingNCT07658170MINIPIGUpdated Jun 18, 2026

Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)

An interventional study of Lipobolus (Autologous Fat + Platelet-Rich Fibrin+Calcium chloride) in Breast Cancer, Lipofilling and Fat Graft, sponsored by The Leningrad Regional Clinical Hospital. Recruiting at 1 site in Russia. Open to female participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-06-18.

Sponsored by The Leningrad Regional Clinical Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Nov 2025, registered Jun 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 69 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 79 studies in Breast Neoplasms with a site in Russia — 12 open to participants now, 48 under way, 24 of them phase 3. Breast Neoplasms · Russia.

Planned enrollment
53rd of 64
30 · median 246
Started
2025
with 7 others
No phase
8 of 79
4 open now
Primary completion
2026-01
later than 19 of 47 live
Registered
78th of 79
by date

Among the 79 studies in Breast Neoplasms with a site in Russia, this one is the 53rd largest by planned enrollment of the 64 interventional ones that give a count, is one of 8 that started in 2025, is one of 8 with no phase, reaches primary completion later than 19 of the 47 other live ones, and was the 78th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 79 studies in Breast Neoplasms with a site in Russia are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 69 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Breast Neoplasms with a site in Russia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a special type of fat graft, made by mixing a person's own fat with platelet-rich fibrin (PRF), works to fix breast shape defects after cancer surgery. PRF is a substance made from a person's own blood that is rich in growth factors, which may help the graft survive better.

The main questions it aims to answer are:

What percentage of the fat graft's volume remains in place 3 months after radiation therapy?

What is the safety of this procedure, including its side effects and any impact on cancer returning?

Participants will:

  • Undergo standard breast-conserving surgery to remove the tumor
  • Have liposuction (fat removal) from their own belly or thighs
  • Receive a "lipobolus" (their own fat mixed with PRF) placed into the breast defect during the same surgery
  • Follow up for 12 months with ultrasound scans, physical exams, and questionnaires (BREASTQ) about their satisfaction and quality of life
03

Conditions studied

  • Breast Cancer
  • Lipofilling
  • Fat Graft
  • Platelet Rich Plasma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 69 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • verified breast cancer (BC).
  • Disease stage from cTis to cT2 according to the TNM classification (AJCC, 8th edition).
  • Tumor grade G1 or G2.
  • Estrogen receptor positivity (ER+).
  • performance status = 0.
  • Primary tumor size up to 2 cm, based solely on preoperative examination data (mammography, ultrasound, MRI).
  • Indications for breast-conserving surgery (BCS) with a breast resection extent determined by a multidisciplinary oncology board.
  • Submission of an informed voluntary consent (IVC) regarding participation in the study.
  • Ability to understand and comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Male gender.
  • ≥ 1.
  • Multifocal or multicentric tumor.
  • Grade G3.
  • Triple-negative or -positive tumor with uncontrolled disease.
  • Stage cT3 or higher or distant (M1).
  • Inflammatory breast cancer.
  • Prior chemotherapy or hormonal therapy.
  • Prior radiation therapy to the breast.
  • Presence of blood coagulation disorders (coagulopathy, thrombocytopathy, thrombocytopenia \< 100 × 10⁹/L).
  • Taking anticoagulants or antiplatelet agents that cannot be temporarily discontinued.
  • Presence of active infectious diseases.
  • Acute diseases.
  • Decompensated comorbidities (diabetes mellitus, cardiovascular diseases, etc.).
  • (BMI) \< 18.5 kg/m² (insufficient adipose tissue volume for liposuction).
  • Pregnancy or lactation.
  • Mental illnesses that prevent .
  • Known allergy to local anesthetics or sodium citrate.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Lipobolus for Breast Defect Reconstruction

    Procedure: Lipobolus (Autologous Fat + Platelet-Rich Fibrin+Calcium chloride)

Interventions

  • ProcedureLipobolus (Autologous Fat + Platelet-Rich Fibrin+Calcium chloride)

    The intervention is a single surgical procedure using a "lipobolus" - a modified fat graft made from the participant's own tissues to restore breast shape after cancer surgery. How it is prepared during surgery: About 200 mL of fat is harvested from the participant's belly using liposuction. Separately, 60 mL of blood is drawn and spun in a centrifuge to obtain platelet-rich plasma (PRP). The fat, PRP, and calcium chloride are mixed. Calcium chloride activates the PRP, forming a thick, gel-like fibrin scaffold that traps the fat fragments into a single, stable block. How it is used: The lipobolus is placed directly into the cavity left after breast-conserving cancer surgery. This allows for immediate volume restoration in one operation. What makes it different: Standard fat grafting uses fat alone and often requires 2-3 procedures due to unpredictable abs

06

What researchers measure

Primary outcomes

  1. Percentage of Lipobolus Volume Retention at 3 Months Post-Radiotherapy

    Volume of the lipobolus that remains viable and engrafted, measured as a percentage of the originally implanted volume. The volume is assessed by breast ultrasound (US) performed 3 months after completion of adjuvant external beam radiotherapy (EBRT). The percentage is calculated as (volume at 3 months post-EBRT / immediate post-operative volume) × 100.

    Time frame: 3 months after completion of radiotherapy

Secondary outcomes

  1. Patient Satisfaction with Aesthetic Results Measured by BREAST-Q

    Change in patient-reported satisfaction and psychosocial well-being assessed using the validated BREAST-Q questionnaire. Two modules are used: (1) Satisfaction with Breasts module, and (2) Psychosocial Well-being module. Higher scores indicate better satisfaction and well-being.

    Time frame: Baseline (pre-operatively), 3 months after radiotherapy, 6 months after radiotherapy, 12 months after surgery

  2. Frequency of Locoregional Recurrence and Distant Metastasis

    The cumulative incidence of locoregional recurrence (recurrence of cancer in the ipsilateral breast, chest wall, or regional lymph nodes) and distant metastasis (spread of cancer to distant organs) during the observation period. Events are confirmed by imaging (mammography, ultrasound, MRI, or CT) and/or biopsy as clinically indicated.

    Time frame: From the date of surgery through 12 months of follow-up (and continuing throughout the study observation period)

  3. Dynamic Changes in Lipobolus Volume Assessed by Ultrasound

    Change in lipobolus volume over time measured by breast ultrasound. Volume is calculated at each time point and compared to the immediate post-operative volume. Data are used to assess the pattern and rate of graft resorption or stability during the first year after surgery.

    Time frame: 7 days after surgery; 1 month after radiotherapy; 3 months after radiotherapy; then every 3 months through 12 months post-surgery (i.e., at 6, 9, and 12 months after surgery)

  4. Type and Frequency of Complications

    The incidence of specific complications occurring after the lipobolus procedure and after radiotherapy. Complications assessed include: oil cysts, fat necrosis, seroma, hematoma, and infection. Events are documented by clinical examination and ultrasound imaging and graded according to CTCAE v5.0 where applicable.

    Time frame: Immediately after the procedure (within 30 days post-surgery) and after completion of radiotherapy (through 12 months of follow-up)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Jan 2026, 2 months.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 2 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2026
First posted
Jun 18, 2026
StartActual
Nov 13, 2025
Primary completionActual
Jan 13, 2026
CompletionEst.
Jun 3, 2028
Last update
Jun 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658170
Lead sponsor
The Leningrad Regional Clinical Hospital
Responsible party
Sponsor
First posted
Jun 18, 2026
Start date
Nov 13, 2025
Primary completion
Jan 13, 2026
Completion
Jun 3, 2028 (estimated)
Last update
Jun 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion